Niacin
- Generic Name
- Niacin
- Brand Names
- Advicor, Concept Ob, Irospan 24/6 Kit, Mvc-fluoride, Niacor, Niaspan, Niodan, Simcor, Vitafol-one
- Drug Type
- Small Molecule
- Chemical Formula
- C6H5NO2
- CAS Number
- 59-67-6
- Unique Ingredient Identifier
- 2679MF687A
- Background
Niacin is a B vitamin used to treat vitamin deficiencies as well as hyperlipidemia, dyslipidemia, hypertriglyceridemia, and to reduce the risk of myocardial infarctions.
- Indication
Niacin is indicated to prevent vitamin deficiencies in pediatric and adult patients receiving parenteral nutrition as part of multivitamin intravenous injections. Niacin oral tablets are indicated as a monotherapy or in combination with simvastatin or lovastatin to treat primary hyperlipidemia and mixed dyslipidemia. It can also be used to reduce the risk of...
- Associated Conditions
- Atherosclerosis, High Cholesterol, High Triglyceride Level, Mixed Dyslipidemias, Nonfatal Myocardial Infarction, Pellagra, Primary Hypercholesterolemia, Severe Hypertriglyceridemia (sHTG), Type II Hyperlipidaemia
- Associated Therapies
- Dietary supplementation
Effect of Nicotinic Acid on Adipose Tissue Inflammation in Obese Subjects
- First Posted Date
- 2010-03-09
- Last Posted Date
- 2020-07-29
- Lead Sponsor
- University Hospital, Toulouse
- Target Recruit Count
- 24
- Registration Number
- NCT01083329
- Locations
- 🇫🇷
Centre d'Investigation Clinique, Purpan University Toulouse Hospital, Toulouse, France
Effects of Niaspan™ on High-density Lipoprotein (HDL) in Healthy Male Subjects (0000-069)
- First Posted Date
- 2010-02-19
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 37
- Registration Number
- NCT01071291
Psilocybin Cancer Anxiety Study
- First Posted Date
- 2009-08-12
- Last Posted Date
- 2020-10-20
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 29
- Registration Number
- NCT00957359
- Locations
- 🇺🇸
NYU College of Dentistry Bluestone Center for Clinical Research, New York, New York, United States
Study to Test GSK256073 in Patients With Dyslipidemia
- Conditions
- Interventions
- First Posted Date
- 2009-05-18
- Last Posted Date
- 2019-12-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 80
- Registration Number
- NCT00903617
- Locations
- 🇺🇸
GSK Investigational Site, Seattle, Washington, United States
Niacin and Endothelial Function in Early CKD
- First Posted Date
- 2009-02-27
- Last Posted Date
- 2014-05-06
- Lead Sponsor
- Tufts Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT00852969
- Locations
- 🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
Evaluate Carotid Artery Plaque Composition by Magnetic Resonance Imaging in People Receiving Cholesterol Medication
- Conditions
- Interventions
- First Posted Date
- 2008-07-15
- Last Posted Date
- 2022-06-07
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 217
- Registration Number
- NCT00715273
- Locations
- 🇺🇸
University of Washington Coronary Atherosclerosis Research Lab, Seattle, Washington, United States
🇺🇸St. Luke's Idaho Cardiology, Boise, Idaho, United States
🇺🇸Yakima Heart Center, Yakima, Washington, United States
Effects of Nicotinic Acid Plus Simvastatin Versus Simvastatin Alone on Carotid and Femoral Intima-Media Thickness in Patients With Peripheral Artery Disease (NASCIT)
- First Posted Date
- 2008-07-09
- Last Posted Date
- 2011-07-22
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 200
- Registration Number
- NCT00712049
- Locations
- 🇦🇹
Medical University Vienna, Vienna, Austria
Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)
- First Posted Date
- 2008-05-30
- Last Posted Date
- 2020-02-06
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 102
- Registration Number
- NCT00687076
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
Assessment of Interaction Between Vytorin and Niaspan in Healthy Subjects (P04955AM2)
- Conditions
- Interventions
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2022-02-16
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 18
- Registration Number
- NCT00652431
Benefit of Elevation of HDL-C on Cardiovascular Outcomes in Women
- Conditions
- First Posted Date
- 2008-01-10
- Last Posted Date
- 2011-09-14
- Lead Sponsor
- Cedars-Sinai Medical Center
- Target Recruit Count
- 43
- Registration Number
- NCT00590629
- Locations
- 🇺🇸
CSMC, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.